<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01742884</url>
  </required_header>
  <id_info>
    <org_study_id>IOBA-Thea-001-2012</org_study_id>
    <nct_id>NCT01742884</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Universitario de Oftalmobiología Aplicada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Universitario de Oftalmobiología Aplicada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Thealoz is effective in Dry Eye Syndrome exposed
      to controlled adverse environmental conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with fluorescein corneal staining reduction of at least 1 point</measure>
    <time_frame>1 Month</time_frame>
    <description>Proportion of subjects with staining reduction within the treatment group vs proportion of staining reduction in control group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>1 month</time_frame>
    <description>Best Corrected Visual Acuity at Exit visit compared to baseline visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>1 month</time_frame>
    <description>Pathological elevations of intraocular pressure from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eye fundus alterations</measure>
    <time_frame>1 month</time_frame>
    <description>Presence of any pathological finding in eye fundus while the patient is in the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal Pachymetry</measure>
    <time_frame>1 month</time_frame>
    <description>Changes in corneal thickness along the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Moderate Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>Thealoz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Thealoz (Trehalose) 3% for 1 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment with Thealoz´s vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with Thealoz´s vehicle for 1 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Thealoz</intervention_name>
    <description>Instillation of 1 drop of Thealoz</description>
    <arm_group_label>Thealoz</arm_group_label>
    <other_name>Thealoz, Trehalose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>1 drop of the vehicle will be instillated in the eye</description>
    <arm_group_label>Treatment with Thealoz´s vehicle</arm_group_label>
    <other_name>Instillation of Thealoz´s vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man/woman ≥ 18 years old, able to freely give consent to participate in the study

          -  Fluorescein corneal staining ≥ 1 and ≤ 3 in Oxford Scales

          -  At least 2 of the following tests altered:

          -  Ocular Surface Disease Index (OSDI) Test symptoms between 12 and 40

          -  BUT ≤10 seconds

          -  Lissamine green conjunctival staining ≥ 1

          -  Schirmer Test without anesthesia ≤ 5 mm

          -  Informed consent signed

          -  Data protection consent signed

        Exclusion Criteria:

          -  Sensitivity or known intolerance to any of the product used in the study

          -  Story of ocular infections or severe ocular inflammation within the 6 previous months
             to study inclusion

          -  Any active ocular pathology other than Dry Eye Syndrome

          -  Any traumatize or ocular surgery that may affect corneal sensitivity and/or normal
             tear distribution (e.g. cataract surgery, refractive surgery) within the 6 previous
             months to study inclusion

          -  Use of contact lenses in the 3 previous months to study inclusion

          -  Use of any ocular topical medications other than the treatment for Dry Eye Syndrome

          -  Ocular treatment for Dry Eye Syndrome with corticosteroids 1 month before inclusion
             visit or Cyclosporin A 3 months before inclusion

          -  Diagnosis of Rosacea or Severe Blepharitis (associated to systemic or ocular
             pathologies) Any severe uncontrolled systemic disease that may affect the eye (except
             for primary or secondary Sjögren)

          -  Start, discontinuation or change within the study of the dosage of antihistaminics,
             cholinergic agents, beta blockers, anti depressants or any other systemic drugs with
             potential effects in the tear film

          -  No pregnant or breastfeeding women is allowed to participate in the study.
             Childbearing potential women must use contraceptive means during the whole study.

          -  Participation in another clinical trial in the last 30 days before study inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Jesus Gonzalez, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IOBA - University of Valladolid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IOBA - University of Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>January 7, 2015</last_update_submitted>
  <last_update_submitted_qc>January 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Eye Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

